Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financi...( milestones and reimbursements earn...)

milestones and reimbursements earned through the company's Wyeth

collaboration

-- Total operating expenses - $55 million to $60 million

-- Operating cash requirements - $28 million to $32 million

Conference Call Details

Trubion will host a conference call and webcast to discuss its third quarter 2007 financial results. The call will be held today at 2 p.m. Pacific Time; 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling 1-888-208-1386 or 913-981-5593. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4262106. The webcast replay will be available in the events section of Trubion's Web site.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit